Kornimate/medical-research-clean huggingface dataset:
functional gastrointestinal disorders in pediatric ibd

Conditions: Inflammatory Bowel Diseases; Functional Gastrointestinal Disorders; Pediatric Disorder; Anxiety Depression; Quality of Life

Summary: background: persistent gastrointestinal symptoms have been described in patients who are considered in remission of their inflammatory bowel disease (ibd). these symptoms, attributed to functional gastrointestinal disorders (fgid) in ibd, may have a significant impact of quality of life, and may be associated with fatigue, anxiety and depression. there is very little data regarding pediatric specificities of these fgid. aims: the aim of the study is to evaluate the prevalence of fgid in pediatric patients with ibd in remission. secondary aims are to investigate a possible association of fgid with fatigue, anxiety, depression and impacted quality of life in the patients, as well as anxiety and depression in the parents. methods: this will be an observational, case-control study. all patients between 9 and 18 years old , with ibd in remission will be invited to participate. questionnaires will be web-based and will evaluate: presence of fgid (fr-qpgs), fatigue (facit-f), anxiety (scared-r), depression (cdi), quality of life (impact-iii). parents will be invited to fill in web-based questionnaires on their symptoms of anxiety (stai/y-a and stai/y-b) and depression (bdi). clinical parameters will be retrieved retrospectively from the chart. level of remission will be confirmed by most recent blood tests and fecal calprotectin. patients with fgid will be compared to patients without fgid in terms of clinical characteristics, disease phenotype and associated psychological comorbidities.


Eligibility criteria:
inclusion criteria: * ibd (crohns disease, ulcerative colitis or ibd-u) * in remission (defined as: physician's global assessment = remission, no nocturnal stools, no blood in stools, \< or = 3 stools/day, c reactive protein \< 10 mg/l, erythrocyte sedimentation rate \< 20 mm, no flare of disease or change of treatment in the last 3 months, no ongoing corticosteroid therapy * followed for ibd for at least 1 year exclusion criteria: * presence of an ileostomy or colostomy * past history of total colectomy * unable to understand written french or to answer the questionnaires
online physical activity tracking in patients with multiple sclerosis

Conditions: Multiple Sclerosis

Summary: this study aims to investigate the effects of regular remote monitoring of physical activity levels of individuals with multiple sclerosis on physical activity levels, psychological health, fatigue and quality of life.

the study population will consist of patients with multiple sclerosis. participants in the intervention and control groups will initially be given a brief briefing about the benefits of exercise training. additionally, a short brochure explaining the effects of exercise in multiple sclerosis will be given. participants in the intervention group will be allowed to join the group created by the researchers via whatsapp. in this regard, it will be emphasized that should exercise at least 3 days a week. the participant will be asked to fill out the survey created via google form in order to record their activity minutes in these three days. the total intervention period will be 8 weeks. reminders to exercise will be given by the researchers in the created whatsapp group. participants in the control group will be encouraged to continue their routine lives. average step counts will be recorded before and after treatment. additionally, they will be asked to report their average step count each week via whatsapp groups. pre- and post-intervention evaluations will be carried out by a physiotherapist. patients' physical activity levels, depression and anxiety, fatigue and quality of life parameters will be examined.

Eligibility criteria:
inclusion criteria: -\>18 years old * being diagnosed with multiple sclerosis according to mcdonald's diagnostic criteria, owning a smartphone and using the whatsapp application, * having regular internet access * not participating in a regular physical activity program in the last 6 months, * expanded disability status scale\<6 exclusion criteria: * having an attack during work, * any orthopedic or neurological disorder that affects compliance with the physical activity program, * not having independent mobility ability

Keywords: physical activity depression life quality multiple sclerosis
anabolic steroids for nutritional rehabilitation of critically ill patients

Conditions: Malnutrition; Critical Illness

Summary: this prospective, double-blinded study will determine the feasibility of determining the efficacy of a weekly intramuscular injection of nandrolone (an anabolic steroid) in malnourished icu patients.the data from this study will also enable us to prepare a future grant proposal with a calculated sample size necessary to demonstrate an improvement in clinical outcome.

critically ill patients are particularly prone to excessive catabolism using skeletal muscle as the primary substrate as a result of maladaptation to critical illness. ultimately, critical illness leads to a significant loss of lean body mass (lbm). for example, a 40% loss of lbm is associated with a 100% mortality. anabolic steroids have been studied and have been shown to improve nutrition in select malnourished patient groups, however, the majority of these studies were not well designed or consisted of small sample sizes. our hypothesis is anabolic steroid administration will result in an augmentation of positive nitrogen balance and lbm. this increase in lbm will result in liberation from mechanical ventilation sooner than the placebo group and will result in discharge from the icu sooner, and as a result, a reduction in morbidity (nosocomial infections) and possibly mortality. all moderately to severly malnourished icu patients who have an anticipated stay in icu \> 10 days, will be randomized to receive nandrolone (25 mg-females, 50 mg;males) once weekly for six weeks or placebo. all patients will receive a standard enteral nutritional regimen. patients will be monitored for assessment of nitrogen balance, lean body mass, and length of time spent on ventilator, in icu and in hosp, and incidence of infections.lean body mass will be measured using a bioimpedance analyzer.

Eligibility criteria:
inclusion criteria: 1. anticipated length of stay in icu \>10 days 2. moderate to severe malnutrition 3. patient tolerating enteral feeds exclusion criteria: 1. age \< 18 yrs 2. known allergy to nandrolone 3. women of child bearing age with positive pregnancy test 4. contraindications to intramuscular injections ie anticoagulation 5. renal failure requiring renal replacement therapy 6. patients with breast or prostate cancer -

Keywords: malnutrition anabolic steroids intensive care unit rehabilitation
sodium channel expression in human teeth

Conditions: Dental Pulp Disease

Summary: the human tooth pulp has many nerve fibers and is a common source of pain. this study examines nerve fibers within normal and painful samples and identifies changes that can contribute to the generation of pain.

the human tooth pulp is a rich source of pain fibers and is a common site of pathology that is often accompanied by spontaneous and stimulus-induced lingering pain. a common treatment modality includes the extraction of the offending tooth diagnosed with irreversible pulpitis. extracted teeth represent an abundant source of normal and diseased human nociceptors and the evaluation of these tissues represents a powerful model to study human pain mechanisms since the character of pain, pain levels, and response to stimuli can be documented prior to extraction. the overall objective of this study is to correlate changes in the expression of sodium channels (nach) with clinical responses to hot and cold thermal stimuli, and the expression of the associated receptors/transducers responsible for receiving that stimulus in extracted teeth with severe and spontaneous pain. teeth requiring extraction in the clinical setting will be used for this study. the research questions are: 1.) to evaluate quantitatively the overall nach and nav 1.3, 1.6, 1.7, 1.8 1.9 isoform expressions in nerves of normal teeth as compared to diseased teeth 2.) to evaluate quantitatively hot/cold vr1 and cmr1 receptor expression in nerves of normal teeth as compared to the nerves in the modality-specific pain groups of diseased teeth 3.) to investigate the ultrastructural localization of nach isoforms in different fiber types and at sites that may be involved in pain generation.

Eligibility criteria:
inclusion criteria: * individuals 16-80 years old * normal third molar(wisdom)teeth * painful, diseased teeth requiring extraction exclusion criteria: * individuals under age 16 or above age 80 * pregnant females * prisoners * nonvital painful teeth

Keywords: pain, sodium channel, dental pulp
a clinical study to evaluate the long-term safety of hrs-1893 in hypertrophic cardiomyopathy

Conditions: Hypertrophic Cardiomyopathy

Summary: this study mainly evaluates the long-term safety of hrs-1893 in subjects with hypertrophic cardiomyopathy.


Eligibility criteria:
inclusion criteria: 1. subjects with hypertrophic cardiomyopathy who have previously completed hrs-1893 related studies. 2. female subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose and must be non-lactating during the study. female subjects of childbearing potential and male subjects whose partners are women of childbearing potential must agree to refrain from donating sperm/eggs from the time they sign the informed consent form until 3 months after the last dose of trial drug, and to comply with relevant contraceptive requirements. 3. understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent form in writing. exclusion criteria: 1. previous history of coronary artery disease (stenosis of one or more coronary arteries \>70%) or myocardial infarction. 2. have received medication for negative inotropic other than disopyramide, β-blocker, verapamil, diltiazem 4 weeks before screening. 3. history of syncope or sustained ventricular tachycardia within 6 months prior to screening. 4. other conditions that the investigator considers the subject to be unsuitable for participating in this trial, such as physical or psychological diseases or conditions that may increase the risk of the trial, affect the subject's compliance with the protocol, or affect the subject's completion of the trial.
microsoft kinect, gait function,hemineglect, vestibulo-ocular training

Conditions: Hemiplegic Gait

Summary: gait problems in hemineglect patient post stroke , vestibuloocular training plays a role in improving gait function, gait assessment using a model based study (microsoft kinect) for pre and post training assesment.

the syndrome of visuospatial neglect is a common consequence of unilateral brain injury. it is most often associated with stroke and is more severe and persistent following right hemisphere damage, with reported frequencies in the acute stage of up to 80%. this may result in gait disturbance, high levels of energy expenditure and increase the risk of falls. vestibuleo-ocular training techniques are aimed at improving or even restoring visual function by training patients to detect stimuli in the blind hemifield and increase their overall sensitivity to them. the investigators propose a model based (microsoft kinect), a device can be used for assessment of spatiotemporal gait variables as well as gait kinematics.

Eligibility criteria:
inclusion criteria: * subjects age will range from (60-70) years old. * patients who had a stroke at least six months prior. * patients who had visual field defects post stroke. * patients who could walk without caretaker assistance or no severe dyskinesias. * adequate hearing (hearing aid if required). * patients who had no problem with their state of consciousness and absence of dementia * patients who had no orthopedic problems that may affect gait. * patients will be chosen in both sexes. * clinically and medically stable. exclusion criteria: patients who will meet one of the following criteria will be excluded from the study: * only one functional eye. * neurological problem or any severe co-morbidity likely to affect gait. * intact visual field. * instability of patient's medical condition. * obese ( bmi ≥ 30 kg∕m2 ). * association with another medical problem that can affect patient
paeoniflorin combination of hepatoprotective drugs versus hepatoprotective drugs only for auto-immune hepatitis

Conditions: Hepatitis, Autoimmune

Summary: an open-label,prospective, randomized pilot study to evaluate the efficacy, safety and tolerability of paeoniflorin, for the treatment of autoimmune hepatitis (aih) with mild necroinflammatory activity on liver biopsy.


Eligibility criteria:
inclusion criteria: * patients aged 20-70 years; * diagnosed with aih or primary biliary cirrhosis-autoimmune hepatitis overlap syndrome based on liver biopsy results and without indication of immunosuppressive therapy; * high levels of alanine aminotransferase (alt) or aspartate aminotransferase (ast)(1-3 x uln); * high levels of igg(1-1.5 x uln); * liver biopsy showed mild lymphocytic piecemeal necrosis (interface hepatitis); * agreed to participate in the trial, and assigned informed consent. exclusion criteria: * the presence of hepatitis a, b, c, d, or e virus infection; * patients with presence of liver cirrhosis or portal hypertension; * patients with presence of fulminant liver failure; * primary sclerosing cholangitis, non-alcoholic steatohepatitis, drug induced liver disease or wilson disease confirmed by liver biopsy; * pregnant and breeding women; * severe disorders of other vital organs, such as severe heart failure, cancer; * parenteral administration of blood or blood products within 6 months before screening; * recent treatment with drugs having known liver toxicity; * taken part in other clinic trials within 6 months before screening.
use of pet-mr in head and neck cancer patients - diagnostic and therapeutic applications

Conditions: Head and Neck Cancer

Summary: the primary research question to be answered in this project is "are patients with locally-advanced head and neck cancer able to tolerate a pet-mri scan when they are immobilised in a radiotherapy treatment shell?" this will be assessed by measuring the proportion of patients that complete the full scanning protocol and by obtaining participant feedback on their experience of completing the scan. the secondary question is "can a pet-mri scan fused with a planning ct scan improve the accuracy in radiotherapy planning of patients with head and neck cancer? accuracy will be assessed by: 1. comparing the radiotherapy target volumes and radiotherapy plans with and without the use of a pet-mri scan. 2. comparing inter- and intra-observer variability in treatment contours with and without the use of a pet-mri scan within and between oncologists and implications of that.


Eligibility criteria:
inclusion criteria: 1. aged 18 years or over 2. able to give informed written consent. 3. new diagnosis of biopsy-proven head and neck cancer. 4. who performance status ≤ 2. 5. mdt-recommended treatment with radical radiotherapy, with or without concurrent systemic therapy. 6. mri and pet-ct staging scans for diagnosis. exclusion criteria: 1. known intolerance/sensitivity to 18f-2-deoxyglucose or gadolinium-containing contrast agents. 2. claustrophobia or other contraindications to mri. 3. unable to pass through a 55 cm hula hoop. 4. female patients that are pregnant or breastfeeding. 5. unable to understand written or spoken english. 6. patients not undergoing radical intent radiotherapy. 7. patients with stage 4 or 5 chronic kidney disease or other biochemical abnormalities e.g. uncontrolled blood glucose levels which can have an impact on pet-mri imaging or contrast administration.

Keywords: head neck cancer pet mri
effect of myofascial release on menstrual pain post caesarean section

Conditions: Menstrual Pain

Summary: the purpose of this study is to investigate the effect of myofascial release on menstrual pain post cesarean section.

egypt has the highest cesarean section (cs) rate that has increased from 20% in 2005 to 52% in 2014. this exceptionally high cs rate without a corresponding improvement in maternal and child mortality suggests that although cs is available for populations at risk, numbers of medical unjustified css are on the rise. the cs scar is assumed to be related to adverse clinical gynecological symptoms such as intermenstrual bleeding, dysmenorrhea, dyspareunia and chronic pelvic pain.the incidence of postpartum dysmenorrhea was significantly higher in the cesarean section delivery than in the vaginal delivery. cesarean scars have direct links to the perineal fascia and its connection with the transversalis fascia. these scars can interfere with fascial load distribution, which create adhesions to neighboring tissues, the abdominal and pelvic viscera and surrounding anatomical structures are then potentially disrupted, causing inadequate nutrition and inappropriately distributed tension among the various structures affected. fascial restrictions obviously decrease blood flow by vascular compression. when the dermis and fasciae are affected by a scar, the sliding structure of the fasciae is altered and when the scar tissues are not capable of adapting to the new stressor, their function is impaired. mfr procedure lead to vasodilation by increasing capillary permeability. mfr directs force to fascial fibroblasts, as well as indirect strains applied to nerves, blood vessels, the lymphatic system and muscles. there is lacking of studies at this point, so the aim of the study is to investigate the effect of myofascial release on menstrual pain post cs.

Eligibility criteria:
inclusion criteria: * women complaining of menstrual pain post - caesarean section (cs). * their age will range from 20 to 35 years. * their body mass index will range from 20-30 kg/m2. * women who gave birth once or twice. * women who had c-section 6 weeks to 6 months ago. exclusion criteria: * active infection/ infectious skin disease, burn or scars. * less than six weeks after cs. * any abdominal surgeries other than cs. * any spinal deformity as scoliosis or kyphosis. * history of cancer or radiation to the abdominopelvic region.
the brigance assessment of individual neurodevelopment in young children with sickle cell disease- 2

Conditions: Sickle Cell Disease

Summary: a preliminary study was conducted involving 88 three-year-old children with sickle cell disease (scd) who were followed at the st. jude children's research hospital sickle cell center. they were offered developmental screening with the brigance preschool screen-ii test during their regular clinic visits from january 2006 to august 2008. data from this work showed that 50% of 3 year old children with scd had low developmental screening scores. in addition, the low scores were found to be associated with less parental education and with speech deficits. however they were not associated with sickle cell genotype and hemoglobin level. the primary goal of this study is to prospectively administer brigance preschool screen -ii to 3 year old children with scd and 3 year old children without scd who come from similar socioeconomic backgrounds and compare the results between the two groups.

the primary objective of this study is to compare development in 3 year old children with scd who are not on any treatment to age matched healthy controls using pass/fail rate for the brigance preschool screen ii. secondary objectives: 1. to compare the raw scores of the brigance preschool screen ii between scd and control groups. 2. to compare the pass/fail rate and the raw scores between scd patients who are not on any treatment and those who are being treated with hydroxyurea. 3. to compare the pass/fail rate and the raw scores between scd patients on hydroxyurea treatment and the healthy controls 4. to assess the influence of medical factors on the brigance preschool screen ii performance in children with scd. 5. to assess the influence of socioeconomic factors on the brigance preschool ii results in children with scd and controls.

Eligibility criteria:
patient group inclusion criteria: * 3.0-\<4.0 years of age * african-american * diagnosis of sickle cell disease (hbss, hbsc, hbsβºthalassemia, hbsβ\^+thalassemia) * followed at st. jude children's research hospital sickle cell center exclusion criteria: * previous stroke * patients who are currently on a chronic transfusion program * known diagnosis associated with significant cognitive impairment (e.g. down syndrome, mental retardation) * previously tested with brigance preschool screen-ii control group inclusion criteria: * 3.0-\<4.0 years of age * african-american * attendee of day-care in memphis area exclusion criteria: 1. known diagnosis associated with significant cognitive impairment (e.g. stroke, down syndrome, mental retardation) 2. known diagnosis sickle cell disease (hbss, hbsc, hbsβºthalassemia, hbsβ\^+thalassemia) 3. previously tested with brigance preschool screen-ii

Keywords: neuro cognitive deficits; brigance pre-school screen;
intestinal wall remodeling (infliximab therapy) in crohn's disease patients undergoing serial computed tomography (ct) enterography

Conditions: Crohn's Disease

Summary: anti-tnf therapy induces intestinal wall remodeling that correlates with clinical response and can be detected in patients undergoing serial computed tomography enterography (cte).

we will retrospectively identify crohn's disease patients who underwent serial cte imaging between 2004 and 2008. approximately 4500 ctes were performed over this period. we estimate a sample size of 50 crohn's disease patients who have had cte performed before and after infliximab therapy was initiated. we will analyze each cte for the presence of penetrating disease, number of inflammatory lesion, length of each lesion, and severity of each lesion (degree of enhancement, wall thickness, stratification, vascular engorgement, fatty proliferation, and symmetry). degree of enhancement and thickness will be graded on a 5-point scale. stratification, vascular engorgement, fatty proliferation, and symmetry will be treated as dichotomous variables (yes/no). only small bowel lesions will be described. a gi radiologist (jgf), blinded to the clinical information and previous imaging results, will provide the readings. comparisons between ctes will be performed to determine responders (all lesions improved), mixed responders (not all lesions improved), and refractory (no lesion improved). a descriptive pattern of healing will also be recorded for each lesion. clinical data to be recorded include indication for cte, time between cte, dates of each cte, date on first infliximab infusion, dose of infliximab, interval between infusions, history of penetrating disease, history of surgery, clinical status at imaging (remission, flare, or uncertain), medication usage, age, and disease duration. clinical status at time of imaging will be based on the ordering clinician's global assessment at the time of repeat cte. this will be determined by a review of the medical record by a gastroenterologist (dhb).

Eligibility criteria:
inclusion criteria * established crohn's disease * cte before and after initiating infliximab * underwent at least 2 ctes between 1/1/2004 and 12/31/2007 * at least 6 months between ctes \*off-label use of infliximab by either increased dose or shortened interval will be included in the study exclusion criteria * small bowel surgery occurring before repeat cte imaging * episodic infliximab therapy (intervals greater than every 8 weeks)